Farah Champsi is Director at Kite Pharma, Inc. (KITE). They have made 8 open-market trades across 4 companies since 2011, most recently 2020-01-22.
CIK 0001198321
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $3.4M since 2011, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| LIFE | 1,778,064 | $66.6M |
| PTLA | 1,116,214 | $20.1M |
| CMRX | 1,714,330 | $14.6M |
| ESPR | 2,052,189 | $6.5M |
| AEGR | 2,464,052 | $4.9M |
| KITE | 1,807 | $325K |
| ALLK | 34,615 | $11K |
| NGSX | 1,735,673 | — |
| Total | $113.1M |
Shares reported on the most recent Form 4, priced at the 2020-01-24 close. 1 holding could not be priced and is excluded from the total.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| KITE | SELL | 2017-06-14 | 2017-06-16 | $89.44 | $2.3M | +16.2% | +15.5% | +102.3% |
| KITE | SELL | 2017-04-27 | 2017-05-01 | $82.75 | $3.2M | -9.7% | -13.0% | +30.5% |
| KITE | SELL | 2017-04-24 | 2017-04-26 | $82.67 | $20.5M | -14.3% | -11.7% | +33.5% |
| KITE | SELL | 2017-04-13 | 2017-04-17 | $82.42 | $19.0M | +0.7% | -14.0% | +24.6% |
| KITE | SELL | 2015-06-30 | 2015-07-02 | $62.35 | $41.4M | -16.7% | +2.4% | +2.4% |
| CMRX | SELL | 2013-10-23 | 2013-10-23 | $15.51 | $6.9M | -19.0% | -1.5% | -1.5% |
| ESPR | BUY | 2013-07-01 | 2013-07-01 | $14.00 | $3.3M | -35.3% | -0.8% | -0.8% |
| AEGR | BUY | 2011-08-08 | 2011-08-09 | $12.44 | $121K | -26.4% | -3.7% | -3.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.